Multimodal analysis of heart biopsy samples
Official title: Multimodal Analysis of Endomyocardial Biopsies
Run by University Hospital, Essen · NCT07359690 · Data updated 2026-11-12
This project will take one extra small heart biopsy during a clinically needed procedure to test whether detailed molecular and immune analyses can find disease-specific signatures in adults with cardiomyopathies, myocarditis, cardiac amyloidosis, or after heart transplant.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 216 (estimated) |
| Sponsor | University Hospital, Essen Academic / other |
| Locations | 1 site (Essen, North Rhine-Westphalia) |
| Status | Recruiting |
| Started | October 27, 2025 |
| Main results expected | September 30, 2028 |
| Study ends | September 30, 2028 |
| Registry record updated | January 22, 2026 |
| Trial ID | NCT07359690 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (over 18) who already have a clinical indication for an endomyocardial biopsy and can give informed consent are the ideal candidates.
✕Probably not a fit
People who are not having an endomyocardial biopsy, minors, pregnant individuals, or those unable to give informed consent are not eligible and will not receive direct benefit from participation, since this is observational research.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
In patients already undergoing a clinically indicated endomyocardial biopsy, the study collects one additional biopsy sample for research. The tissue will undergo multimodal laboratory testing including multi-omics (proteome, lipidome, metabolome), immune signalling analyses, and nuclear cardiology-related assays. Results will be compared with clinical parameters, biomarkers, and diagnostic data to identify molecular profiles linked to specific myocardial diseases and post-transplant courses. The goal is to discover diagnostic markers and mechanistic insights that could guide future diagnostics or therapy development.
Why it matters
Potential benefit: If successful, the work could lead to more precise diagnostic markers and better-targeted treatments for different myocardial diseases and transplant complications.
How similar studies have gone: Previous multi-omics and immune profiling studies of heart tissue have shown promise in identifying disease-associated signatures, but comprehensive multimodal approaches combining several omics and signalling analyses are still relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged \>18 years with a clinical indication for endomyocardial biopsy. * Patients capable of providing informed consent who have signed the consent form for participation in the study. Exclusion Criteria: * Patients without a clinical indication for endomyocardial biopsy (EMB). * Pregnant individuals. * Patients incapable of providing informed consent. * Women of childbearing potential who are not using adequate contraception.
Where it's running
-
Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University Hospital Essen, Germany
Essen, North Rhine-Westphalia, Germany Recruiting
Study contacts
- Principal investigator: Lars Michel, PD Dr. med. — Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center Essen, University Hospital Essen, Germany
- Study coordinator: Lars Michel, PD Dr. med.
- Email: lars.michel@uk-essen.de
- Phone: +49 0201 723 84841
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Identifying patients with cardiomyopathy for potential heart transplantation
This study is trying to find new ways to identify and understand cardiomyopathy in patients to better predict if they might need a heart transplant in the future.
-
T1 mapping to characterize heart tissue in common heart diseases
This project tests whether T1 mapping MRI scans, including dye-free native T1, can define normal and disease-specific heart tissue values for adults with various heart conditions.
-
Registry for patients with non-ischemic cardiomyopathies
This study is collecting information from people with non-ischemic cardiomyopathies to see how to better diagnose and manage their condition and predict potential heart rhythm problems.
-
Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS
Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.
-
Liver and Coagulation Markers in ATTR Cardiac Amyloidosis
This study tests liver function and blood-clotting markers in people with ATTR-CA to see if they reflect disease severity and progression.
-
Detecting cardiac amyloidosis in people with severe aortic valve narrowing
This study tests non-invasively whether imaging tests can find heart amyloidosis in patients with severe aortic stenosis who are being evaluated for valve replacement.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.